NCT07095985

Brief Summary

This is a single-center retrospective cohort study conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). The study aims to evaluate the safety and clinical efficacy of a novel anastomotic technique designed to reconstruct ileocecal valve (ICV) function during laparoscopic right hemicolectomy for right-sided colon cancer. Background: Standard right hemicolectomy necessitates resection of the ICV, a critical structure regulating ileocolonic transit and acting as a bacterial barrier. Its loss can lead to small intestinal bacterial overgrowth (SIBO), diarrhea, malabsorption, and reduced quality of life. While preserving the ICV is ideal when oncologically feasible, it's often unavoidable. This study proposes an innovative anastomosis technique ("Revolute Insert Side-End Ileocecal Valve Reconstruction" - "RISE anastomosis") to functionally reconstruct the ICV. Study Design: Population: 50 patients who underwent laparoscopic right hemicolectomy at the center, meeting inclusion/exclusion criteria (age 18-80, ASA ≤3, primary tumors in appendix, cecum, ascending colon, hepatic flexure, or proximal 1/3 transverse colon, complete data). Groups: Conventional Anastomosis Group (n=30): Standard side-to-side ileocolic anastomosis using a linear stapler. RISE anastomosis Group (n=20): Novel technique involving everting the ileal stump with sutures to create an artificial valve, then implanting it into an incision on the colonic wall and suturing it circumferentially. Primary Objective: Assess safety and feasibility of RISE anastomosis. Secondary Objective: Evaluate the clinical efficacy of RISE anastomosis on bowel function recovery. Key Outcomes: Safety (Primary): 30-day postoperative complications (anastomotic leak, bleeding, stricture), severe complications (Clavien-Dindo). Efficacy (Secondary): Time to first flatus, first defecation, first formed stool; Bristol stool scale; defecation frequency/urgency; incontinence rates; length of stay; reoperation/readmission rates. Other: Operative time, anastomosis time, blood loss, lymph node yield, inflammatory markers, follow-up assessments (contrast studies, endoscopy). Data Analysis: Data extracted from electronic medical records. Statistical analysis using SPSS 22.0 (χ² test for categorical data, t-test for normally distributed continuous data; significance p\<0.05). Ethics: Approved by the institutional ethics committee. Conducted in accordance with the Declaration of Helsinki and Chinese regulations. Patient privacy and data confidentiality are prioritized. Timeline: Patient data collection and analysis (Jun-Aug 2024); Statistical analysis and manuscript preparation (Sep-Dec 2024). Significance: This study investigates a potentially transformative surgical technique. If proven safe and effective, RISE anastomosis could significantly improve postoperative bowel function and quality of life for patients requiring ICV resection during right hemicolectomy, addressing a major unmet clinical need related to ICV loss.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 30, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 26, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 31, 2025

Completed
Last Updated

July 31, 2025

Status Verified

July 1, 2025

Enrollment Period

2 months

First QC Date

June 26, 2025

Last Update Submit

July 29, 2025

Conditions

Keywords

Right hemicolectomyIleocecal valve reconstructionRISE anastomosisLaparoscopic surgeryColon cancerAnastomotic techniqueBowel functionRetrospective cohort study

Outcome Measures

Primary Outcomes (1)

  • 30-day postoperative complications (anastomotic leak, bleeding, stricture), severe complications (Clavien-Dindo).

    After the surgery, continuously record whether the patient has any adverse reactions until 30 days postoperatively, and score the severity of the adverse reactions according to the Clavien-Dindo classification.

    from day1 to day30 after surgery

Secondary Outcomes (2)

  • Time to first flatus

    from day1 to day7 after surgery

  • Time to first formed stool

    from day1 to day30 after surgery

Other Outcomes (4)

  • Operative time

    During the operation

  • Anastomosis time

    During the operation

  • Blood loss

    During the operation

  • +1 more other outcomes

Study Arms (2)

RISE anastomosis

Following right hemicolectomy, the novel RISE-ICVR technique involves everting the ileal stump to create an artificial valve, implanting it into a colonic wall incision, and securing it with circumferential sutures.

Conventional Anastomosis Group

In contrast, the conventional approach uses a linear stapler to perform a side-to-side ileocolic anastomosis.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The patients who visited Xinqiao Hospital and were diagnosed with right-sided colon cancer

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical status classification of II-III.
  • Patients newly diagnosed with tumors located in the appendix, ileocecal region, ascending colon, hepatic flexure, or the right one-third of the transverse colon, or those scheduled to undergo laparoscopic right hemicolectomy.
  • No history of other gastrointestinal diseases (excluding intestinal polyps and gallstones).
  • Willingness to participate in the study with signed informed consent.
  • Complete clinical data available.

You may not qualify if:

  • Presence of malignancies in other anatomical sites.
  • Tumor invasion into adjacent organs.
  • Presence of infectious or autoimmune diseases (e.g., Crohn's disease).
  • Congenital or acquired metabolic disorders.
  • Use of antibiotics or other microbiota-altering medications within one month before enrollment.
  • Changes in surgical plan such that the resection does not include the ileocecal valve.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xinqiao Hospital

Chongqing, Chongqing Municipality, 400037, China

Location

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Study Officials

  • Weidong Xiao, MD

    Second Affiliated Hospital of Army Medical University

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of General Surgery, Clinical Professor

Study Record Dates

First Submitted

June 26, 2025

First Posted

July 31, 2025

Study Start

July 1, 2024

Primary Completion

August 30, 2024

Study Completion

December 30, 2024

Last Updated

July 31, 2025

Record last verified: 2025-07

Locations